Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Glucagon-like peptide GLP

Appetite-suppressing. Neuropqrtide modulators and gut hormones with anorexigenic effects are a-melanocortin-stimulating hormone (a-MSH), cocaine- and amphetamine-regulated transcript (CART), glucagon-like peptide-1 (GLP-1), leptin, insulin, oxyntomodulin, pancreatic peptide PP, peptide YY and PYY3 36, and others. [Pg.90]

Glucagon-like peptide 1 (GLP-1) in biology and pathology. Diabetes/ Metabolism Research and Reviews, 21, 91-117 (d) Drucker, D.J. and Nauck, M. [Pg.418]

Improved stability with simultaneous preservation of activity has been demonstrated with analogues of glucagon-like peptide-1 and gastric inhibitory polypeptide, two hormones that stimulate the release of insulin. Glucagon-like peptide-1 (GLP-1) is a 30-residue gastrointestinal hormone, ami-dated at the C-terminus that has potential as a treatment for type-2 diabetes. However, GLP-1 is rapidly degraded by dipeptidyl-peptidase IV (EC... [Pg.342]

The incretin hormone glucagon-like peptide-1 (GLP-1) plays a crucial role in the regulation of insulin by acting on the pancreas to potentiate glucose-induced insulin secretion. GLP-1 is rapidly cleaved by serine protease dipeptidylpeptidase IV. The inhibitors of DDP-IV are new drugs for the oral treatment of type 2 diabetes. [Pg.332]

Nauck MA. Glucagon-like peptide 1 (GLP-1) and incretin mimetics for the treatment of diabetes. Pract Diabetes Int 2005 22 171-9. [Pg.390]

Several peptide products used in the treatment of diabetes mellitus, in addition to insulin, are currently administered by subcutaneous injection and these drugs are candidates for development of nasal formulations. Glucagon-like peptide-1 (GLP-l)-related peptides stimulate the insulin response to glucose and diminish the release of glucagon after a meal. These effects diminish the excessive postprandial increase in glucose observed after a meal in persons with type 2 diabetes mellitus. GLP-1-related peptides must be administered by subcutaneous injection before meals in order to be effective. This requirement for injection before each meal is likely to impact the utilization of these products by persons with type 2 diabetes. Exendin-4 is a GLP-1-related peptide with a molecular mass of 4.2 kDa. The development of a GLP-1-related peptide nasal formulation containing an absorption enhancer would allow patients to scll-administer one of these drugs just before a meal without the need for a subcutaneous injection. [Pg.386]

The approval of sitagliptin (1) by the U.S. FDA in 2006 established dipeptidyl peptidase IV (DPP-4) inhibitors as an important new therapy for the treatment of type 2 diabetes.4 7 DPP-4 inhibitors stimulate insulin secretion indirectly by enhancing the action of the incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (G1P). GLP-1 and G1P stimulate insulin secretion in a... [Pg.125]

Glucagon-like peptide-1 (GLP-1) agonists Liraglutide Saxagliptin... [Pg.381]

See other pages where Glucagon-like peptide GLP is mentioned: [Pg.159]    [Pg.211]    [Pg.424]    [Pg.538]    [Pg.1493]    [Pg.657]    [Pg.92]    [Pg.451]    [Pg.265]    [Pg.471]    [Pg.97]    [Pg.131]    [Pg.403]    [Pg.401]    [Pg.297]    [Pg.125]    [Pg.57]    [Pg.757]    [Pg.726]    [Pg.947]    [Pg.388]    [Pg.26]    [Pg.320]    [Pg.341]    [Pg.159]    [Pg.166]    [Pg.343]    [Pg.159]    [Pg.211]    [Pg.424]    [Pg.538]    [Pg.24]    [Pg.58]    [Pg.1024]    [Pg.11]   
See also in sourсe #XX -- [ Pg.125 , Pg.126 , Pg.129 ]

See also in sourсe #XX -- [ Pg.112 ]

See also in sourсe #XX -- [ Pg.56 , Pg.57 ]

See also in sourсe #XX -- [ Pg.130 , Pg.157 , Pg.158 ]

See also in sourсe #XX -- [ Pg.247 ]

See also in sourсe #XX -- [ Pg.71 ]

See also in sourсe #XX -- [ Pg.400 ]



SEARCH



GLP

GLP-1 peptide

Glucagon

Glucagon-like peptide

Peptide glucagons

© 2024 chempedia.info